Full Year 2023 Nova Eye Medical Ltd Earnings Call Transcript
(technical difficulty)
So our first target is the sum of A, B and C, which is about 1,200 customers. When we get through to D, this D section, which is the large volume of cataract and comprehensive surgeons, we estimate about 10,000 of those in the United States. So we have a very systematic approach, starting with our active accounts. We go then to our inactive accounts. We proceed to new accounts who we call co-surgeons, and then we move to the cataract and refractive. This is our very targeted sales plan that we're working with our field sales team. Remember, we have a team of employees sales people including trainers in the United States, boots on the ground, pushing our device into the hands of surgeons.
Next slide. The glaucoma opportunity is a large one. Glaucoma is -- has been treated for many years with drops, $6.1 billion market nominally. The aging population drives a prevalence and general growth in that number in developed countries. But within that market, there's a need for glaucoma surgical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |